Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
- Conditions
- Secondary Progressive Multiple Sclerosis
- Registration Number
- NCT05826028
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in Australia to Mayzent (siponimod) treatment.
Initiating siponimod involves pre-screen tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. The MSGo platform was developed to support onboarding. It is an integrated digital platform that functions as a patient support service.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 368
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Average time for siponimod onboarding Up to 168 days
- Secondary Outcome Measures
Name Time Method Time to siponimod onboarding in pre-specified sub-groups Up to 168 days Percentage of patients who adhered to the titration protocol Up to 168 days Time on maintenance therapy Up to 168 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Novartis Investigational Site
🇦🇺St Leonards, New South Wales, Australia
Novartis Investigational Site🇦🇺St Leonards, New South Wales, Australia